Effects of gastrointestinal stimulant and suppressant pretreatment on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic.
The effects of pretreatment with the gastrointestinal stimulant domperidone and the suppressant scopolamine butylbromide on the absorption of AS-924, a novel prodrug-type cephem antibiotic, were investigated in six healthy adult male volunteers by a cross-over method. The T(max) of ceftizoxime (CTIZ), the active moiety of AS-924, was slightly prolonged by scopolamine butylbromide (T(max)=1.8 vs. 1.5 h for the group without pretreatment). However, there were no significant differences in pharmacokinetic parameters including T(max), cumulative urinary excretion rates of CTIZ and cumulative urinary excretion rates of pivaloylcarnitine for 12 h after the dosing between the pretreated and control groups. Domperidone did not affect the absorption of AS-924.
Yanagawa
A
A
Medical Research Center, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, 216-0015, Kanagawa, Japan.
Shimada
J
J
Mori
N
N
Sugihara
T
T
Sakai
A
A
Yamaji
S
S
Yano
K
K
Kitamura
T
T
Kano
T
T
D000328:Adult; D002086:Butylscopolammonium Bromide / Q000008:administration & dosage / Q000494:pharmacology*; D015296:Ceftizoxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004294:Domperidone / Q000008:administration & dosage / Q000494:pharmacology*; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D008297:Male; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014556:Urine / Q000737:chemistry
D005765:Gastrointestinal Agents; D011355:Prodrugs; D002086:Butylscopolammonium Bromide; C121334:ceftizoxime alapivoxil; D004294:Domperidone; D015296:Ceftizoxime